| Date | Time | Source | | | 05/08/2013 | 4:00PM | PRNUS | Cadence Pharmaceuticals To Present At Three Investment Conferences During The Month Of May 2013
Cadence Pharmaceuticals To Present At Three Investment Conferences During The Month Of May 2013 PR Newswire SAN DIEGO, May 8, 2013 SAN DIEGO, May 8, 2013 /PRNewswire/ -- Cadence Pharmaceuticals, Inc. (NASDAQ: CADX), a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary products... More...>> |
| 05/06/2013 | 8:38AM | ZACKS | Narrower-than-Expected Loss at Cadence - Analyst Blog
Cadence Pharmaceuticals, Inc. (CADX) posted an adjusted net loss of 13 cents per share in the first quarter of 2013, narrower than the Zacks Consensus Estimate of a loss of 14 cents. The loss reported by the company in the year-ago quarter was 27 cents per share. Cadence Pharma reported net revenues of $23.6 million, up... More...>> |
| 05/02/2013 | 4:00PM | PRNUS | Cadence Pharmaceuticals Reports First Quarter 2013 Financial Results
Cadence Pharmaceuticals Reports First Quarter 2013 Financial Results PR Newswire SAN DIEGO, May 2, 2013 SAN DIEGO, May 2, 2013 /PRNewswire/ -- Cadence Pharmaceuticals, Inc. (NASDAQ: CADX), a biopharmaceutical company focused on acquiring, in-licensing, developing and commercializing proprietary products principally for... More...>> |
| 04/25/2013 | 4:00PM | PRNUS | Cadence Pharmaceuticals To Host Conference Call And Webcast To Discuss First Quarter 2013 Financial Results On May 2, 2013
Cadence Pharmaceuticals To Host Conference Call And Webcast To Discuss First Quarter 2013 Financial Results On May 2, 2013 PR Newswire SAN DIEGO, April 25, 2013 SAN DIEGO, April 25, 2013 /PRNewswire/ -- Cadence Pharmaceuticals, Inc. (NASDAQ: CADX), a biopharmaceutical company focused on acquiring, in-licensing, developing... More...>> |
| 03/18/2013 | 1:25PM | ZACKS | Good News for Cadence Pharma - Analyst Blog
Cadence Pharmaceuticals, Inc. (CADX) recently announced that its Ofirmev (acetaminophen) injection has been made available on the Veterans Affairs National Formulary (VANF) by the Department of Veterans Affairs (VA). Cadence Pharma believes that the availability of Ofirmev on the VANF list confirms VA’s recognition... More...>> |
| 03/14/2013 | 4:00PM | PRNUS | Cadence Pharmaceuticals Appoints Stephen L. Newman, M.D., to its Board of Directors
Cadence Pharmaceuticals Appoints Stephen L. Newman, M.D., to its Board of Directors PR Newswire SAN DIEGO, March 14, 2013 SAN DIEGO, March 14, 2013 /PRNewswire/ -- Cadence Pharmaceuticals, Inc. (NASDAQ: CADX), a biopharmaceutical company focused on acquiring, in-licensing, developing and commercializing proprietary products... More...>> |
| 03/12/2013 | 10:43AM | ZACKS | Narrower-Than-Expected Loss at CADX in 4Q - Analyst Blog
Cadence Pharmaceuticals, Inc. (CADX) posted an adjusted net loss of 15 cents per share in the fourth quarter of 2012, narrower than the Zacks Consensus Estimate by a penny. The loss reported in the year-ago quarter was 37 cents per share. Cadence Pharma reported net revenues of $17.1 million, up 192% year over year and... More...>> |
| 03/12/2013 | 8:00AM | PRNUS | Cadence Pharmaceuticals Announces the Availability of OFIRMEV® (acetaminophen) Injection through the VA National Formulary
Cadence Pharmaceuticals Announces the Availability of OFIRMEV® (acetaminophen) Injection through the VA National Formulary PR Newswire SAN DIEGO, March 12, 2013 SAN DIEGO, March 12, 2013 /PRNewswire/ -- Cadence Pharmaceuticals, Inc. (NASDAQ: CADX), announced today that the Department of Veterans Affairs has made OFIRMEV®... More...>> |
| 03/07/2013 | 7:30AM | PRNUS | Cadence Pharmaceuticals Reports Fourth Quarter and Full Year 2012 Financial Results
Cadence Pharmaceuticals Reports Fourth Quarter and Full Year 2012 Financial Results -- 2012 Net Product Revenue Exceeds $50 Million -- PR Newswire SAN DIEGO, March 7, 2013 SAN DIEGO, March 7, 2013 /PRNewswire/ -- Cadence Pharmaceuticals, Inc. (NASDAQ: CADX), a biopharmaceutical company focused on acquiring, in-licensing... More...>> |
| 03/06/2013 | 8:23PM | PRNUS | Cadence Pharmaceuticals Announces Strategic Plan to Secure Long-Term Manufacture and Supply of OFIRMEV® (acetaminophen) Inje...
Cadence Pharmaceuticals Announces Strategic Plan to Secure Long-Term Manufacture and Supply of OFIRMEV® (acetaminophen) Injection PR Newswire SAN DIEGO, March 6, 2013 SAN DIEGO, March 6, 2013 /PRNewswire/ -- Cadence Pharmaceuticals, Inc. (NASDAQ: CADX), a biopharmaceutical company focused on acquiring, in-licensing... More...>> |
| 02/28/2013 | 4:15PM | PRNUS | Cadence Pharmaceuticals To Host Conference Call And Webcast To Discuss Fourth Quarter And Full Year 2012 Financial Results On...
Cadence Pharmaceuticals To Host Conference Call And Webcast To Discuss Fourth Quarter And Full Year 2012 Financial Results On March 7, 2013 PR Newswire SAN DIEGO, Feb. 28, 2013 SAN DIEGO, Feb. 28, 2013 /PRNewswire/ -- Cadence Pharmaceuticals, Inc. (NASDAQ: CADX), a biopharmaceutical company focused on acquiring, in-licensing... More...>> |
| 02/26/2013 | 4:00PM | PRNUS | Cadence Pharmaceuticals' CEO Ted Schroeder To Present At The Cowen & Company 33rd Annual Health Care Conference In Boston On ...
Cadence Pharmaceuticals' CEO Ted Schroeder To Present At The Cowen & Company 33rd Annual Health Care Conference In Boston On March 5, 2013 PR Newswire SAN DIEGO, Feb. 26, 2013 SAN DIEGO, Feb. 26, 2013 /PRNewswire/ -- Cadence Pharmaceuticals, Inc. (NASDAQ: CADX), a biopharmaceutical company focused on acquiring... More...>> |
| 02/06/2013 | 5:32PM | PRNUS | Cadence Pharmaceuticals' CEO Ted Schroeder To Present At The Leerink Swann Global Healthcare Conference In New York City On F...
Cadence Pharmaceuticals' CEO Ted Schroeder To Present At The Leerink Swann Global Healthcare Conference In New York City On February 13, 2013 /* Style Definitions */ span.prnews_span { font-size:8pt; font-family:"Arial"; color:black; } a.prnews_a { color:blue; } li.prnews_li { font-size:8pt; font-family:"Arial"; color:black;... More...>> |
| 01/25/2013 | 1:20PM | ZACKS | Cadence Forecasts Ofirmev Sales - Analyst Blog
Cadence Pharmaceuticals Inc. (CADX) recently announced that it expects preliminary net revenue of Ofirmev (acetaminophen) injection to be approximately $17.1 million for the fourth quarter. Thepreliminary revenue guidance is above the earlier projection of approximately $15.9 million to $16.4 million issued during the... More...>> |
| 01/24/2013 | 8:45AM | MWUS | Free Research Reports on AMD, CADX, MYRX and SWY Issued by the Bedford Report
The Bedford Report has released new equity reports today. As a leading provider of free in depth reports and timely market updates, Bedford is an essential resource for hundreds of thousands of investors across the country. Advanced Micro Devices, Inc. (NYSE: AMD) shares of the semiconductor company surged over 11 percent... More...>> |
| 01/23/2013 | 7:30AM | PRNUS | Cadence Pharmaceuticals Estimates Fourth Quarter 2012 Net Product Revenue and Provides Full Year 2013 Revenue Guidance
Cadence Pharmaceuticals Estimates Fourth Quarter 2012 Net Product Revenue and Provides Full Year 2013 Revenue Guidance /* Style Definitions */ span.prnews_span { font-size:8pt; font-family:"Arial"; color:black; } a.prnews_a { color:blue; } li.prnews_li { font-size:8pt; font-family:"Arial"; color:black; } p.prnews_p { font-size:0.62em;... More...>> |
| 01/21/2013 | 8:20AM | MWUS | Major Revenue Losses From Patent Expirations Forces Big Pharma Companies to Look to the Biotech Industry for Replacements
Lost revenues from expiring patents has played a major part in the Biotech Industry's success in recent years. A total of 676 takeovers of biotechnology and pharmaceutical companies have occurred in the past three years, with an average premium of 38 percent, according to data collected by Bloomberg. Five Star Equities... More...>> |
| 01/11/2013 | 12:34PM | ZACKS | The Medicines Co. Acquires Incline - Analyst Blog
The Medicines Company (MDCO) recently announced that it has completed its acquisition of Incline Therapeutics, Inc., for an upfront fee of $185 million. In addition, The Medicines Company will shell out up to $205 million on the achievement of regulatory and commercial targets With this acquisition, Ionsys... More...>> |
| 12/12/2012 | 8:11AM | DJN | Medicines Agrees to Buy Incline; Reaches Collaboration Deal With Bristol-Myers
By Tess Stynes Medicines Co. (MDCO) agreed to acquire privately held Incline Therapeutics Inc. for $185 million plus potential milestone payments as it also reached a licensing agreement and two-year collaboration deal with Bristol-Myers Squibb Co. (BMY) on its Recothrom topical treatment to control bleeding during surgery... More...>> |
| 12/12/2012 | 7:04AM | PRNUS | Cadence Pharmaceuticals Announces Termination of Option Agreement to Acquire Incline Therapeutics, Inc.
Cadence Pharmaceuticals Announces Termination of Option Agreement to Acquire Incline Therapeutics, Inc. /* Style Definitions */ span.prnews_span { font-size:8pt; font-family:"Arial"; color:black; } a.prnews_a { color:blue; } li.prnews_li { font-size:8pt; font-family:"Arial"; color:black; } p.prnews_p { font-size:8pt; font-family:"Arial";... More...>> |
|
